Drug facts
BrandIzervay (Avacincaptad Pegol)
No generic avacincaptad pegol is approved; the latest Izervay patent or exclusivity in the Orange Book runs to 07/11/2034.
Izervay was first approved by the FDA on 08/04/2023 under NDA 217225; the application holder is Astellas Pharma US Inc.
Holder Astellas Pharma US IncApplication NDA 217225Approved 08/04/2023
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
2,810days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved08/04/2023
Last patent07/11/2034
2024202620282030203220342036
- Latest patent
- 07/11/2034Izervay Orange Book
02Competition
- Generics
- No generic approved Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Izervay profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Astellas Pharma US Inc Orange Book
- Application
- NDA 217225 Orange Book
- First approved
- 08/04/2023 Orange Book
- Dosage forms
- solution
- Routes
- intravitreal
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.